Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Alzamend Neuro Inc

Healthcare US ALZN

1.15USD
0.01(0.88%)

Last update at 2026-06-03T20:00:00Z

Day Range

1.111.16
LowHigh

52 Week Range

0.846.48
LowHigh

Fundamentals

  • Previous Close 1.14
  • Market Cap4.22M
  • Volume33934
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-6.93916M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-3.67

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Type yearly yearly yearly yearly yearly
Date 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Income before tax -4.51485M -9.94800M -14.87817M -12.36206M -5.04657M
Minority interest - - - - -
Net income -4.51485M -9.94800M -14.87817M -12.40458M -5.20366M
Selling general administrative 3.08M 3.48M 6.68M 7.12M 3.64M
Selling and marketing expenses - 0.25M 0.74M - -
Gross profit -0.05074M -0.05074M - - -
Reconciled depreciation 0.05M 0.05M 0.02M 0.00355M -
Ebit -4.49682M -9.93774M -14.87047M -12.31954M -4.95189M
Ebitda -4.44608M -9.88700M -14.84740M -12.31599M -4.95018M
Depreciation and amortization 0.05M 0.05M 0.02M 0.00355M 0.00171M
Non operating income net other - - - 0.00400M 0.06M
Operating income -4.49682M -9.93800M -14.87047M -12.31954M -4.95189M
Other operating expenses 4.50M 9.94M 14.87M 12.32M 4.95M
Interest expense 0.02M 0.01M 0.00770M 0.05M 0.16M
Tax provision - - - - -
Interest income - - - 0.00000M 0.00171M
Net interest income -0.01803M -0.01010M -0.00770M -0.04652M -0.15710M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - 0.04M 0.16M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 4.45M 9.94M 14.87M 12.32M 4.95M
Cost of revenue 0.05M 0.05M - - -
Total other income expense net -0.01803M -0.01010M -0.00770M -0.04252M -0.09468M
Discontinued operations - - - - -
Net income from continuing ops -4.51485M -9.94775M -14.87817M -12.36206M -5.04657M
Net income applicable to common shares - - -14.87817M -12.36206M -5.04657M
Preferred stock and other adjustments - - - - -
Breakdown 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Type yearly yearly yearly yearly yearly
Date 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Total assets 4.60M 0.63M 5.92M 14.52M 2.91M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.23M 0.08M 0.69M 0.35M 0.98M
Total liab 0.63M 3.23M 2.87M 1.16M 0.90M
Total stockholder equity 3.97M -2.59418M 3.05M 13.35M 2.01M
Deferred long term liab - - - - -
Other current liab - 3.23M 2.87M 0.00208M 0.06M
Common stock 0.00008M 0.00007M 0.00969M 0.00955M 0.00674M
Capital stock 0.00008M 0.00007M 0.00969M 0.00955M 0.00682M
Retained earnings -58.53526M -54.02041M -44.07266M -29.19449M -16.83244M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 3.95M 0.38M 5.14M 14.06M 1.93M
Cash and equivalents - - - - -
Total current liabilities 0.63M 3.23M 2.87M 1.16M 0.90M
Current deferred revenue - -3.22577M - - -
Net debt -3.94866M -0.07533M -5.14086M -14.06381M -1.59397M
Short term debt - 0.30M - - 0.34M
Short long term debt - 0.30M - - 0.34M
Short long term debt total - 0.30M - - 0.34M
Other stockholder equity 62.50M 51.43M 47.11M 42.54M 18.84M
Property plant equipment - - 0.08M 0.10M -
Total current assets 4.18M 0.46M 5.84M 14.41M 2.91M
Long term investments - - - - -
Net tangible assets - - 3.05M 13.35M 2.01M
Short term investments - - - - -
Net receivables - - - - 0.02M
Long term debt - - - - -
Inventory - - - - -0.01621M
Accounts payable 0.63M 2.93M 2.87M 1.16M 0.50M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.00000M - - -
Additional paid in capital - - - - -
Common stock total equity - - 0.00969M 0.00955M 0.00674M
Preferred stock total equity - - - - 0.00007M
Retained earnings total equity - - -44.07266M -29.19449M -16.83244M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.43M 0.18M 0.08M 0.10M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Type yearly yearly yearly yearly yearly
Date 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Investments -0.30000M -0.14724M 0.00000M -0.10646M 0.10M
Change to liabilities - - 1.71M 0.69M -0.41324M
Total cashflows from investing activities -0.30000M -0.14724M - -0.10646M 0.10M
Net borrowings 0.00000M 0.30M - -0.05867M 2.25M
Total cash from financing activities 10.44M 3.65M 0.00020M 18.85M 4.45M
Change to operating activities - - 0.64M 0.63M 0.26M
Net income -4.51485M -9.94775M -14.87817M -12.36206M -5.04657M
Change in cash 3.57M -4.76481M -8.92295M 12.13M 1.84M
Begin period cash flow 0.38M 5.14M 14.06M 1.93M 0.09M
End period cash flow 3.95M 0.38M 5.14M 14.06M 1.93M
Total cash from operating activities -6.56819M -8.26999M -8.92315M -6.61399M -2.71203M
Issuance of capital stock 10.44M 3.35M 0.00000M 18.91M 2.10M
Depreciation 0.05M 0.05M 0.02M 0.00355M 0.12M
Other cashflows from investing activities - - - -0.10646M 0.10M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - 0.00020M 6.00M 2.10M
Other cashflows from financing activities 7.74M 2.10M -0.98913M 0.00220M 2.35M
Change to netincome - - 3.58M 4.40M 2.49M
Capital expenditures 0.30M 0.15M 0.00000M 0.11M 0.11M
Change receivables - - - - -
Cash flows other operating - - 0.64M 0.63M 0.65M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - -8.92295M 12.13M 1.84M
Change in working capital -2.43847M 0.67M 2.35M 1.33M -0.15245M
Stock based compensation 0.33M 0.96M 3.58M 4.41M 2.03M
Other non cash items 0.00929M 0.00071M 1.71M 0.00877M 0.45M
Free cash flow -6.86819M -8.41724M -8.92315M -6.72045M -2.71203M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ALZN
Alzamend Neuro Inc		 0.01 0.88% 1.15 - - - 1.93 -3.1332
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Alzamend Neuro Inc

3480 Peachtree Road NE, Atlanta, GA, United States, 30326

Key Executives

Name Title Year Born
Mr. Stephan Jackman CEO & Director 1976
Mr. Kenneth S. Cragun CPA Sr. VP of Fin. 1961
Mr. David J. Katzoff Chief Financial Officer 1962
Mr. Henry C. W. Nisser Esq. Exec. VP, Gen. Counsel & Director 1969
Mr. Stephan Jackman CEO & Director 1977
Mr. David J. Katzoff Chief Financial Officer 1963
Mr. Milton Charles Ault III Founder & Vice Chairman 1970
Mr. Henry C. W. Nisser Esq. Executive VP, General Counsel & Director 1970
Mr. Kenneth S. Cragun CPA Senior Vice President of Finance 1961
Mr. Henry C. W. Nisser Esq. Executive VP, General Counsel & Director 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions